344355
AS1842856
≥98% (HPLC), solid, Foxo1 inhibitor, Calbiochem®
别名:
Foxo1 抑制剂，AS1842856
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C18H22FN3O3
化学文摘社编号:
分子量:
347.38
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
Storage condition:
OK to freeze, protect from light
产品名称
Foxo1 抑制剂，AS1842856, Foxo1 Inhibitor, AS1842856, is a cell-permeable inhibitor that blocks the transcription activity of Foxo1 (IC50 = 33 nM). Directly binds to the active Foxo1, but not the Ser256-phosphorylated form.
Quality Level
assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
off-white to tan, tan to yellow
solubility
DMSO: 5 mg/mL
shipped in
ambient
storage temp.
2-8°C
SMILES string
O=C1C(C(O)=O)=CN(C2=C1C(N)=C(F)C(NC3CCCCC3)=C2)CC
InChI
1S/C18H22FN3O3/c1-2-22-9-11(18(24)25)17(23)14-13(22)8-12(15(19)16(14)20)21-10-6-4-3-5-7-10/h8-10,21H,2-7,20H2,1H3,(H,24,25)
InChI key
MOMCHYGXXYBDCD-UHFFFAOYSA-N
General description
一种细胞可渗透性的氧代二氢喹啉，比功能相关的Foxo3a和Foxo4优先抑制Forkhead box O家族成员Foxo1的转录活性（在基于HepG2的报告基因分析中分别抑制70%，20%和3%；[AS184256]=100 nM），通过直接结合非Ser256磷酸化/活性Foxo1，而不是Ser256磷酸化/非活性形式的Foxo1以剂量依赖性方式（IC50=33 nM）结合。在体内26小时禁食期间，显示可在体外大鼠肝瘤Fao培养物（针对PEPCK和G6Pase mRNA水平，IC50=37和130 nM；针对葡萄糖的产生，IC50 =43 nM）和在正常血糖ICR小鼠（分别抑制肝G6Pase和PEPCK mRNA水平的60%和45%；3个在0、12、24小时的100 mg/kg p.o.剂量）以及糖尿病db/db小鼠的鼠肝中（对肝G6Pase，ABCG8，ABCG5，PEPCK，IL-1β和apoCIII mRNA水平分别为86%，70%，56%，48%，35%和31%；3个在0、12、24小时的100 mg/kg p.o.剂量）抑制糖异生。
Packaging
用惰性气体包装
Preparation Note
复溶后，等分并冷冻保存（-20°C）。储备溶液在-20°C下可稳定保存至多3个月。
Other Notes
Nagashima, T., et al. 2010.Mol.Pharmacol.78, 961.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
毒性：监管审查（Z）
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
相关内容
New Products: Antibodies, Assays, Small Molecules, Inhibitors, and Proteins
Jaco Selle et al.
Nature communications, 13(1), 4352-4352 (2022-07-28)
Obesity is a pre-disposing condition for chronic obstructive pulmonary disease, asthma, and pulmonary arterial hypertension. Accumulating evidence suggests that metabolic influences during development can determine chronic lung diseases (CLD). We demonstrate that maternal obesity causes early metabolic disorder in the
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 344355-10MG | 07790788059712 |